There are 2949 resources available
903P - Combination of nivolumab with brentuximab vedotin in therapy of relapsed and refractory Hodgkin lymphoma
Presenter: Liudmila Fedorova
Session: E-Poster Display
Resources:
Abstract
904P - The role of arginine/citrulline cycle disorders in the liver injury pathogenesis in acute myeloid leukemia patients with concomitant obesity
Presenter: Ganna Maslova
Session: E-Poster Display
Resources:
Abstract
909P - Efficacy and safety of HHPG-19K for prophylaxis of chemotherapy-induced neutropenia in patients with lymphoma
Presenter: Meijing Zheng
Session: E-Poster Display
Resources:
Abstract
920P - Avelumab (anti-PD-L1) in patients with platinum-refractory/ineligible recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Results from a phase Ib cohort
Presenter: Joel Guigay
Session: E-Poster Display
Resources:
Abstract
921P - Pembrolizumab plus docetaxel for the treatment of recurrent metastatic head and neck cancer: A prospective phase I/II study
Presenter: Thorsten Fuereder
Session: E-Poster Display
Resources:
Abstract
922P - EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas
Presenter: Martin Forster
Session: E-Poster Display
Resources:
Abstract
923P - Immune alterations in a window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Joseph Curry
Session: E-Poster Display
Resources:
Abstract
924P - SNS-301 added to pembrolizumab in patients (Pts) with ASPH+ advanced squamous cell carcinoma of the head & neck (SCCHN)
Presenter: Alain Algazi
Session: E-Poster Display
Resources:
Abstract
925P - Efficacy of 2nd line treatment with chemotherapy (CT) or immune checkpoint inhibitors (ICIs) for patients (pts) with a prolonged objective response (>6 months) after 1st line therapy for recurrent or metastatic head & neck squamous cell carcinoma (R/M-HNSCC)
Presenter: Agathe Vienne
Session: E-Poster Display
Resources:
Abstract
926P - Real-world data in the era of immune checkpoint inhibitors (ICIs): Cetuximab-containing first-line therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Presenter: Cheng Fu-ming
Session: E-Poster Display
Resources:
Abstract